LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

Strona główna・Stock List・AbCellera Biologics Inc

AbCellera Biologics Inc

Open

SectorHealthcare

3.61 -2.96

Buy Sell

Overview

Share price change

24h

Current

Min

3.57

Max

3.7199999999999998

Key metrics
By Trading Economics
Income	-22M -57M
Sales	-8.1M 9M
EPS	-0.19
Profit margin	-637.845
Employees	596
EBITDA	-1.4M -40M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+80.76% upside

Market Stats
By TradingEconomics
Market Cap	-491M 1.1B
Previous open	6.57
Previous close	3.61

News Sentiment

By Acuity

81%

19%

354 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.99 / 2.635 Support & Resistance

AbCellera Biologics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 gru 2025, 21:41 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 gru 2025, 14:57 UTC

Acquisitions, Mergers, Takeovers

Accenture to Acquire Cabel Industry from Fibonacci Group

25 gru 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 gru 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 gru 2025, 00:20 UTC

Acquisitions, Mergers, Takeovers

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 gru 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 gru 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 gru 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 gru 2025, 19:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

24 gru 2025, 19:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 gru 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 gru 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 gru 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

24 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 gru 2025, 17:08 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 gru 2025, 16:53 UTC

Acquisitions, Mergers, Takeovers

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 gru 2025, 16:31 UTC

Market Talk

Acquisitions, Mergers, Takeovers

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 gru 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 gru 2025, 16:17 UTC

Market Talk

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 gru 2025, 15:33 UTC

Acquisitions, Mergers, Takeovers

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 gru 2025, 15:30 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 gru 2025, 15:19 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 gru 2025, 14:49 UTC

Acquisitions, Mergers, Takeovers

Mexico's Ollamani Sells Stake in Azteca Stadium

24 gru 2025, 14:19 UTC

Market Talk

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 gru 2025, 14:08 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 gru 2025, 14:06 UTC

Market Talk

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 gru 2025, 13:24 UTC

Market Talk

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 gru 2025, 12:59 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 gru 2025, 12:51 UTC

Acquisitions, Mergers, Takeovers

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Peer Comparison

Price change

AbCellera Biologics Inc Forecast

Price Target

By TipRanks

80.76% upside

12 Months Forecast

Average 6.67 USD 80.76%

High 9 USD

Low 4 USD

Based on 5 Wall Street analysts offering 12 month price targets forAbCellera Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to AbCellera Biologics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.99 / 2.635Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

354 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.